GB2105193A - Pharmaceutical compositions containing non-steroidal anti-inflammatory agents - Google Patents

Pharmaceutical compositions containing non-steroidal anti-inflammatory agents Download PDF

Info

Publication number
GB2105193A
GB2105193A GB08225177A GB8225177A GB2105193A GB 2105193 A GB2105193 A GB 2105193A GB 08225177 A GB08225177 A GB 08225177A GB 8225177 A GB8225177 A GB 8225177A GB 2105193 A GB2105193 A GB 2105193A
Authority
GB
United Kingdom
Prior art keywords
ranitidine
pharmaceutical composition
indomethacin
inflammatory drug
steroidal anti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
GB08225177A
Other versions
GB2105193B (en
Inventor
Alan Sinclair Marriott
Andrew Roland Mackenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to CY139882A priority Critical patent/CY1398A/en
Priority to GB08225177A priority patent/GB2105193B/en
Publication of GB2105193A publication Critical patent/GB2105193A/en
Application granted granted Critical
Publication of GB2105193B publication Critical patent/GB2105193B/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to a pharmaceutical composition comprising a systemic non-steroidal anti- inflammatory drug together with the histamine H2-antagonist ranitidine or a physiologically acceptable salt thereof. The histamine H2-antagonist reduces gastric mucosal lesions caused by the anti-inflammatory drug.

Description

SPECIFICATION Pharmaceutical compositions This invention relates to improvements in the formulation of anti-inflammatory drugs.
Systemic non-steroidal anti-inflammatory drugs, such as aspirin, indomethacin and ibuprofen, are known to give rise to undesirable side effects. In particular, they are known to be ulcerogenic and can thus, for example, give rise to gastric ulceration when administered orally. This side effect may be further enhanced in combination with other factors such as stress. Since in some treatments these compounds may have to be used for an extended period, such side effects can prove a serious disadvantage.
Ranitidine is the approved name for N-[2-[[[5-(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl-N'- methyl-2-nitro-1 ,1 -ethenediamine which is described and claimed in British Patent Specification 1,565,966. It is a potent histamine H2-antagonist which may be used in the treatment of conditions where there is an advantage in lowering gastric acidity, particularly in gastric and peptic ulceration, and in the treatment of allergic and inflammatory conditions where histamine is a known mediator. It has now been discovered that mucosal lesions of the gastrointestinal tract caused by systemic non-steroidal anti-inflammatory drugs can be significantly reduced by co-administering ranitidine.
The present invention provides a pharmaceutical composition comprising a systemic non-steroidal anti-inflammatory drug ad ranitidine or a physiologically acceptable salt thereof.
Particularly useful pharmaceutical compositions according to the invention are those in a form suitable for oral or rectal administration.
The systemic non-steroidal anti-inflammatory drugs which may be employed in the invention generally also show analgesic activity and include, for example, aspirin, indomethacin, ibuprofen, fenoprofen, ketoprofen, naproxen, mefenamic acid, diflunisal, benorylate, azapropazone, diclofenac, fenbufen, feprazone, fenclofenac, flufenamic acid, flurbiprofen, oxyphenbutazone, phenylbutazone, piroxicam, sulindac and tolmetin. They may be used in the pharmaceutical compositions of the invention in their usual dosage amounts, e.g. 50mg - 1 g of aspirin, 10 - 100mg of indomethacin and 100 - 500mg of ibuprofen per dosage unit taken one or more times daily in accordance with the normal dosage regime for the drug in question.
It is preferred that ranitidine should be employed in the composition in the form of a physiologically acceptable salt. Such salts include salts of inorganic or organic acids such as the hydrochloride, hydrobromide, sulphate, acetate, maleate, succinate and fumarate salts. The hydrochloride salt is particularly preferred. The amount of ranitidine, preferably in the form a physiologically acceptable salt, employed in the pharmaceutical composition of the invention will be an amount sufficient to reduce the gastrointestinal distress caused by the anti-inflammatory drug and will preferably be in the range of 10 200mg per dosage unit.
The pharmaceutical compositions of the invention may be presented in a conventional manner with the aid of at least one pharmaceutical carrier or excipient. The composition may take the form of, for example, tablets, capsules, powders, granules, solutions, syrups, suspensions, or suppositories, prepared by conventional means with acceptable excipients. The composition may thus contain as excipients, for example, binding agents, compression aids, fillers, lubricants, disintegrants and wetting agents. If desired, other active ingredients may also be present in such compositions. Tablets may be coated in conventional manner, for example, with a suitable film-forming material such as methyl cellulose, ethyl cellulose and/or hydroxypropylmethyl cellulose or with sugar. Liquid preparations may also contain, for example, edible oils such as peanut oil.Suppositories may contain, for example, fat-soluble or water miscible bases.
The pharmaceutical compositions of the invention may be prepared according to conventional techniques well known in the pharmaceutical industry. Thus, for example, the anti-inflammatory drug and the ranitidine or ranitidine salt may be admixed together, if desired, with suitable excipients. Tablets may be prepared, for example, by direct compression of such a mixture. Capsules may be prepared by filling the blend along with suitable excipients into gelatin capsules, using a suitable filling machine.
Alternatively, the pharmaceutical compositions of the invention may be presented in a suitable controlled release form so that the ranitidine or its salt is rapidly made available for absorption and the non-steroidal anti-inflammatory drug is released more slowly. The pharmaceutical compositions may thus be presented for oral or rectal administration in a conventional manner associated with controlled release forms.
The pharmaceutical compositions of the invention maybe used in the treatment of inflammatory conditions, particularly acute and chronic musculo-skeletal inflammatory conditions such as rheumatoid and osteoarthritis and ankylosing spondylitis, and for analgesia in conditions such as dysmenorrhoea, especially where the use of the anti-inflammatory drug is limited by gastro-intenstinal side-effects.
In order that the invention may be more fully understood, the following Examples are given by way of illustration only.
Example 1- TABLETS (a) mg/tablet Ranitidine hydrochloride 168.00* Ibuprofen 400.00 Lactose 387.00 Hydroxypropyl methylcel lulose 5.00 Sodium starch glycollate 30.00 Magnesium stearate 10.00 Compressive weight 1000.00 *Equivalent to 150 mg ranitidine base The ranitidine hydrochloride and ibuprofen are sieved through a 250 ptm sieve and blended with the lactose. This mix is granulated with a solution of the hydroxypropyl methylcellulose. The granules are dried, screened and blended with the sodium starch glycollate and the magnesium stearate. The lubricated granules are compressed into tablets using 12.5mm punches.
(b) mg/tablet Ranitidine hydrochloride 168.00 Indomethacin 50.00 Microcrystalline cellulose 79.00 Magnesium stearate 3.00 Compression weight 300.00 The ranitidine hydrochloride and indomethacin are blended with the microcrystalline cellulose and magnesium stearate and compressed using 9.5mm punches.
Example 2 - CAPSULES (a) capsule Ranitidine hydrochloride 168.00 Ibuprofen 400.00 Starch 1500** 228.00 Magnesium stearate 4.00 Fill weight 800.00 ** A form of directly compressible starch supplied by Colorcon Ltd, Orpington, Kent.
The ranitidine hydrochloride and ibuprofen are sieved through a 250 Wm sieve and blended with the Starch 1500 and magnesium stearate. The resultant mix is filled into size 0 hard gelatin capsules using a suitable filling machine.
(b) mg/capsule Ranitidine hydrochloride 168.00 Indomethacin 50.00 Starch 1500 80.50 Magnesium stearate 1.50 Fill weight 300.00 The ranitidine hydrochloride and indomethacin are sieved through a 250 Fm sieve and blended with the Starch 1500 and magnesium stearate. The resultant mix is filled into size 2 hard gelatin capsules using a suitable filling machine.

Claims (7)

1. A pharmaceutical composition comprising a systemic non-steroidal anti-inflammatory drug and ranitidine or a physiologically acceptable salt thereof.
2. A phrarmaceutical composition as claimed in claim 1 in which the anti-inflammatory drug is aspirin, indomethacin, ibuprofen, fenoprofen, ketoprofen, naproxen, mefenamic acid, diflunisal, benorylate, azapropazone, diclofenac, fenbufen, feprazone, fenclofenac, flufenamic acid, flurbiprofen, oxyphenbutazone, phenylbutazone, piroxicam, sulindac or tolmetin.
3. A pharamaceutical composition as claimed in claim 1 or 2, also including at least one pharmaceutical carrier or excipient.
4. A pharmaceutical composition as claimed in any of claims 1 to 3 in a form suitable for oral or rectal administration.
5. A pharmaceutical composition as claimed in claim 4 in which the anti-inflammatory drug is indomethacin or ibuprnfen.
6. A pharmaceutical composition as claimed in claim 5 which contains 10 - 100 mg of indomethacin or 100 - 500 mg of ibuprofen per dosage unit and 10 - 200 mg of ranitidine or a physiologically acceptable salt thereof per dosage unit.
7. A pharmaceutical composition as claimed in any of claims 1 to 6 in which the ranitidine is used in the form of the hydrochloride salt.
GB08225177A 1981-09-04 1982-09-03 Pharmaceutical compositions containing non-steroidal anti-inflammatory agents Expired GB2105193B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CY139882A CY1398A (en) 1981-09-04 1982-09-03 Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
GB08225177A GB2105193B (en) 1981-09-04 1982-09-03 Pharmaceutical compositions containing non-steroidal anti-inflammatory agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8126786 1981-09-04
GB08225177A GB2105193B (en) 1981-09-04 1982-09-03 Pharmaceutical compositions containing non-steroidal anti-inflammatory agents

Publications (2)

Publication Number Publication Date
GB2105193A true GB2105193A (en) 1983-03-23
GB2105193B GB2105193B (en) 1984-09-12

Family

ID=26280636

Family Applications (1)

Application Number Title Priority Date Filing Date
GB08225177A Expired GB2105193B (en) 1981-09-04 1982-09-03 Pharmaceutical compositions containing non-steroidal anti-inflammatory agents

Country Status (2)

Country Link
CY (1) CY1398A (en)
GB (1) GB2105193B (en)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567179A (en) * 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
US4636498A (en) * 1984-10-11 1987-01-13 Pfizer Inc. Formulation of antiinflammatory drugs
EP0320550A1 (en) * 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
EP0320551A1 (en) * 1986-03-04 1989-06-21 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers
EP0321613A1 (en) * 1987-12-18 1989-06-28 Bristol-Myers Company The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
FR2627985A1 (en) * 1988-03-04 1989-09-08 Glaxo Group Ltd COADMINISTRATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND SUFOTIDINE OR ONE OF ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
BE1002295A5 (en) * 1988-07-07 1990-11-20 Glaxo Group Ltd DRUGS.
GB2191693B (en) * 1986-06-18 1991-01-09 Frederick Jacob Bloomfield 5-lipoxygenase pathway inhibitors.
EP0426479A1 (en) * 1989-11-02 1991-05-08 McNEIL-PPC, INC. Use of a composition for the manufacture of a medicament for curing the symptoms of overindulgence
US5071842A (en) * 1988-10-14 1991-12-10 Bristol-Myers Squibb Company Aspirin-containing composition including diphenhydramine and an alkalizing agent to reduce gastrointestinal injury potential
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
FR2684554A1 (en) * 1991-12-06 1993-06-11 Glaxo Group Ltd MEDICINES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OR FOR ANALGESIA.
WO1994007541A1 (en) * 1992-09-29 1994-04-14 Merck & Co., Inc. Ibuprofen-h2 antagonist combinations
WO1994014431A1 (en) * 1992-12-29 1994-07-07 Richter Gedeon Vegyészeti Gyár Rt. Gastrocytoprotective pharmaceutical composition and process for the preparation thereof
US6926907B2 (en) 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US7736666B2 (en) 2000-03-08 2010-06-15 Nicox S.A. Self emulsifying drug delivery system
US7759307B2 (en) 1998-04-08 2010-07-20 Theta Biomedical Consulting & Development Co., Inc. Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US7815933B2 (en) 2001-09-07 2010-10-19 Nicox S.A. Self emulsifying drug delivery system
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9801824B2 (en) 2008-09-09 2017-10-31 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9987231B2 (en) 2011-12-28 2018-06-05 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0178124A1 (en) * 1984-10-11 1986-04-16 Pfizer Inc. Improved antiinflammatory salts of piroxicam
US4636498A (en) * 1984-10-11 1987-01-13 Pfizer Inc. Formulation of antiinflammatory drugs
US4567179A (en) * 1984-10-11 1986-01-28 Pfizer, Inc. Antiinflammatory salts of piroxicam
EP0320551A1 (en) * 1986-03-04 1989-06-21 Bristol-Myers Company Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2 receptor blockers
GB2191693B (en) * 1986-06-18 1991-01-09 Frederick Jacob Bloomfield 5-lipoxygenase pathway inhibitors.
EP0320550A1 (en) * 1987-12-18 1989-06-21 Bristol-Myers Company Non steroidal anti-inflammatory drug composition containing H1 blockers, H2 blockers, beta adrenergic agonists or combinations thereof and an alkalizing agent
EP0321613A1 (en) * 1987-12-18 1989-06-28 Bristol-Myers Company The effect of a combination of a beta-adrenergic agonist and certain histamine H1- and/or H2-receptor blockers on gastrointestinal injury produced by nonsteroidal anti-inflammatory compositions
FR2627985A1 (en) * 1988-03-04 1989-09-08 Glaxo Group Ltd COADMINISTRATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUG AND SUFOTIDINE OR ONE OF ITS PHYSIOLOGICALLY ACCEPTABLE SALTS
BE1002256A3 (en) * 1988-03-04 1990-11-06 Glaxo Group Ltd DRUGS.
BE1002295A5 (en) * 1988-07-07 1990-11-20 Glaxo Group Ltd DRUGS.
US4983621A (en) * 1988-07-07 1991-01-08 Glaxo Group Limited Medicaments
US5071842A (en) * 1988-10-14 1991-12-10 Bristol-Myers Squibb Company Aspirin-containing composition including diphenhydramine and an alkalizing agent to reduce gastrointestinal injury potential
EP0426479A1 (en) * 1989-11-02 1991-05-08 McNEIL-PPC, INC. Use of a composition for the manufacture of a medicament for curing the symptoms of overindulgence
GR900100786A (en) * 1989-11-02 1992-04-17 Mcneil Ppc Inc A process for providing a composition an analgesic in combination with a h1 or h2 receptor blocker proto n pump ihibitor or combination thereof
US5204118A (en) * 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
AU646230B2 (en) * 1989-11-02 1994-02-17 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5417980A (en) * 1989-11-02 1995-05-23 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5466436A (en) * 1991-12-06 1995-11-14 Glaxo Group Limited Medicaments for treating inflammatory conditions or for analgesia
BE1007268A3 (en) * 1991-12-06 1995-05-09 Glaxo Group Ltd MEDICINES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OR FOR ANALGESIA.
EP0550083A1 (en) * 1991-12-06 1993-07-07 Glaxo Group Limited Medicaments for treating imflammatory conditions or for analgesia containing a NSAID and canitidine bismuth citrate
FR2684554A1 (en) * 1991-12-06 1993-06-11 Glaxo Group Ltd MEDICINES FOR THE TREATMENT OF INFLAMMATORY CONDITIONS OR FOR ANALGESIA.
AT401468B (en) * 1991-12-06 1996-09-25 Glaxo Group Ltd PHARMACEUTICAL COMPOSITIONS CONTAINING RANITIDE INISMUTCITRATE
WO1994007541A1 (en) * 1992-09-29 1994-04-14 Merck & Co., Inc. Ibuprofen-h2 antagonist combinations
WO1994014431A1 (en) * 1992-12-29 1994-07-07 Richter Gedeon Vegyészeti Gyár Rt. Gastrocytoprotective pharmaceutical composition and process for the preparation thereof
US7799766B2 (en) 1998-04-08 2010-09-21 Theta Biomedical Consulting & Development Co., Inc. Composition for treating hormonally-dependent cancers
US7759307B2 (en) 1998-04-08 2010-07-20 Theta Biomedical Consulting & Development Co., Inc. Compositions for protection against superficial vasodilator flush syndrome, and methods of use
US7906153B2 (en) 1998-04-08 2011-03-15 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating multiple sclerosis
US8268365B2 (en) 1998-04-08 2012-09-18 Theta Biomedical Consulting & Development Co., Inc. Anti-inflammatory compositions for treating brain inflammation
US7736666B2 (en) 2000-03-08 2010-06-15 Nicox S.A. Self emulsifying drug delivery system
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US6926907B2 (en) 2001-06-01 2005-08-09 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US9707181B2 (en) 2001-06-01 2017-07-18 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US7815933B2 (en) 2001-09-07 2010-10-19 Nicox S.A. Self emulsifying drug delivery system
US7923043B2 (en) 2004-03-30 2011-04-12 Theta Biomedical Consulting & Development Co., Inc. Method for protecting humans against superficial vasodilator flush syndrome
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8309127B2 (en) 2007-11-30 2012-11-13 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8318202B2 (en) 2007-11-30 2012-11-27 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8449910B2 (en) 2007-11-30 2013-05-28 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8501228B2 (en) 2007-11-30 2013-08-06 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US9801824B2 (en) 2008-09-09 2017-10-31 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
US9050275B2 (en) 2009-08-03 2015-06-09 Theta Biomedical Consulting & Development Co., Inc. Methods of screening for and treating autism spectrum disorders and compositions for same
US9176146B2 (en) 2009-08-03 2015-11-03 Theta Biomedical Consulting & Development Co., Inc. Methods of treating autism spectrum disorders and compositions for same
US9987231B2 (en) 2011-12-28 2018-06-05 Pozen Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid
US10603283B2 (en) 2011-12-28 2020-03-31 Genus Lifesciences, Inc. Compositions and methods for delivery of omeprazole plus acetylsalicylic acid

Also Published As

Publication number Publication date
CY1398A (en) 1987-12-18
GB2105193B (en) 1984-09-12

Similar Documents

Publication Publication Date Title
GB2105193A (en) Pharmaceutical compositions containing non-steroidal anti-inflammatory agents
US5456918A (en) Ranitidine pharmaceutical compositions
US4066756A (en) Therapeutic compositions of 1,3-bis(2-carboxychromon-5-yloxyl)propan-2-ol and aspirin or indomethacin
EP1879566B1 (en) Compositions and methods for inhibiting gastric acid secretion
US20050163847A1 (en) Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug
US5466436A (en) Medicaments for treating inflammatory conditions or for analgesia
FR2904774A1 (en) SOLID PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A REGULATOR AGENT FOR INTESTINAL MOTILITY AND AN ANTIFLATULENT.
WO1993017679A1 (en) Compositions containing ranitidine/bismuth carboxylates salts
US4232012A (en) Composition
GB2216413A (en) Medicaments containing sufotidine
AU6295598A (en) Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine
US4880742A (en) Prostaglandin biosynthesis inhibitors
JPH0296525A (en) Medicine
NL193821C (en) Pharmaceutical preparation.
GB2105588A (en) Pharmaceutical compositions containing non-steroidal anti- inflammatory agents
AU4127599A (en) Pharmaceutical tablets comprising an nsaid and a prostaglandin
KR19990067264A (en) Sustained release cisapride
JPWO2004017954A1 (en) Diclofenac side effect reducing agent
WO2019240310A1 (en) Complex formulation comprising aceclofenac and esomeprazole and method of preparing same
CN1146150A (en) Low dosage ranitidine compositions

Legal Events

Date Code Title Description
PE20 Patent expired after termination of 20 years

Effective date: 20020902